Cargando…
Pembrolizumab for all
The current approval indications for pembrolizumab are complex, reflecting the inclusion criteria of numerous clinical trials that led to approvals. Here we argue that allowing the use of pembrolizumab to any advanced solid tumor in any tumor type in any line of therapy for a fixed duration may be p...
Autores principales: | Kim, Myung S., Prasad, Vinay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984312/ https://www.ncbi.nlm.nih.gov/pubmed/36271954 http://dx.doi.org/10.1007/s00432-022-04412-4 |
Ejemplares similares
-
Pembrolizumab in relapsed or refractory Richter syndrome
por: Armand, Philippe, et al.
Publicado: (2020) -
Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as “toxic epidermal necrolysis-like”
por: Eldani, Céline, et al.
Publicado: (2023) -
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023) -
Annotations for all by all - the BioSapiens network
por: Thornton, Janet
Publicado: (2009) -
Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
por: Olivier, Timothée, et al.
Publicado: (2023)